- Home
- ANSC vs PROK Comparison
ANSC vs PROK Comparison
Compare ANSC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$2.36
Company Overview
Basic Information| Metric | ANSC | PROK |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.6M | 417.1M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANSC | PROK |
|---|---|---|
| Price | $11.17 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 87.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | ★ $744,000.00 |
| Revenue This Year | N/A | $918.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $54.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.43 | $0.46 |
| 52 Week High | $11.17 | $7.13 |
Technical Indicators
Market Signals| Indicator | ANSC | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 71.74 | 49.85 |
| Support Level | $11.13 | $2.06 |
| Resistance Level | $11.10 | $2.29 |
| Average True Range (ATR) | 0.03 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 100.00 | 50.00 |
Price Performance
Historical Comparison ANSC
PROK
About ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.